<p>/PRNewswire/ -- <strong>Kazia Therapeutics Limited (NASDAQ: KZIA)</strong> 是一家專注於腫瘤學的藥物開發公司，今天宣佈已與一些知名的機構和合格投資者簽署了一項證券購買協議，以進行私募股權融資（PIPE）。根據證券購買協議，公司同意向投資者提供和出售總計約 5000 萬美元的普通股和預先融資的認股權證，每股的購買價格相當於每個美國存托股票（ADS）5.00 美元，每個 ADS 代表 500 股普通股。該 PIPE 融資結構為簡單的股權投資，沒有普通認股權證的覆蓋。PIPE 融資由專注於醫療保健的投資者主導，包括 Adar1 Capital Management LLC、Ikarian Capital LLC、Stonepine Capital Management、Velan Capital Investment Management LP 和 Revach Capital Management, LLC，以及現有股東 Jorey Chernett。該交易預計將在 2025 年 12 月 3 日星期三完成，具體取決於慣例的交割條件。</p>
<p>Konik Capital Partners, LLC 作為該 PIPE 的獨家配售代理。</p>
<p>預計公司從 PIPE 中獲得的淨收益約為 4650 萬美元，扣除配售代理費用和公司需支付的其他估計發行費用。公司目前打算將此次發行的淨收益與現有現金、現金等價物和可交易證券結合使用，以支持其主要項目 paxalisib 的持續臨牀開發，該藥物是一種能夠穿透大腦的雙重 PI3K/mTOR 抑制劑，目前正在進行針對腦癌和晚期乳腺癌的臨牀試驗，推進 PD-L1 降解劑項目，以及用於一般企業用途。公司預計，PIPE 的淨收益與現有現金和現金等價物結合，將使其現金儲備延續到 2028 年下半年。</p>
<p>在此次 PIPE 中出售的證券是在不涉及公開發行的交易中進行的，未根據《1933 年證券法》及其修訂版或適用的州證券法進行註冊，且在沒有有效註冊聲明或適用的註冊豁免的情況下，可能無法在美國提供或出售。根據證券購買協議，公司已同意在交割後 30 天內向美國證券交易委員會（SEC）提交一份貨架註冊聲明，以註冊代表普通股的 ADS 及其下方的預融資認股權證的轉售。</p>
<p>本新聞稿不構成出售證券的要約或購買證券的邀請，也不應在任何州或司法管轄區進行這些證券的銷售，除非在該州或司法管轄區的證券法下注冊或合格之前。根據轉售註冊聲明的任何證券發行將僅通過招股説明書進行。</p>
<p><strong>關於 Kazia Therapeutics Limited</strong></p>
<p>Kazia Therapeutics Limited (NASDAQ: <strong>KZIA</strong>) 是一家創新的腫瘤學藥物開發公司，總部位於澳大利亞悉尼。我們的主要項目是 paxalisib，一種能夠穿透大腦的全 PI3K/mTOR 抑制劑，正在開發用於治療多種形式的腦癌，包括膠質母細胞瘤和腦轉移。Phase 1b 臨牀試驗也在進行中，評估 paxalisib 與檢查點抑制劑和化療聯合使用，針對晚期三陰性乳腺癌患者。EVT801，一種選擇性 VEGFR3 抑制劑，目前正在進行針對晚期實體瘤的 Phase 1 臨牀試驗。Kazia 正在努力快速推進這些資產的臨牀開發並走向商業化。</p>
<p><strong>前瞻性聲明</strong></p>
<p>本公告可能包含前瞻性聲明，符合 1995 年《私人證券訴訟改革法》的定義，這些聲明通常可以通過使用 “可能”、“將”、“估計”、“未來”、“前瞻”、“預期” 或其他類似詞語來識別。任何描述 Kazia 未來計劃、戰略、意圖、期望、目標、目標或前景的聲明，以及其他非歷史事實的聲明，也都是前瞻性聲明，包括但不限於關於：PIPE 的完成、相關的慣例交割條件的滿足、PIPE 收益的預期用途、PIPE 完成後公司現金儲備延續到 2028 年下半年的預期，以及公司的未來期望、計劃和前景。這些聲明基於 Kazia 對未來事件和影響其業務的未來趨勢的當前期望和預測，並受到某些風險和不確定性的影響，這些風險和不確定性可能導致實際結果與前瞻性聲明中預期的結果有重大差異，包括與市場和其他條件相關的風險、與臨牀和前臨牀試驗及產品開發相關的風險，包括初步或中期數據可能不反映最終結果的風險、與監管批准相關的風險，以及與全球經濟狀況的影響相關的風險。這些及其他風險和不確定性在 Kazia 最近提交給 SEC 的 20-F 表格年度報告中有更詳細的描述，以及在隨後的 SEC 文件中。Kazia 沒有義務公開更新任何前瞻性聲明，無論是由於新信息、未來事件還是其他原因，除非法律要求。投資者不應對這些前瞻性聲明過於依賴，這些聲明僅適用於本公告的日期。</p>
<p><strong>如需進一步信息，請聯繫：</strong></p>
<p>Alex Star</p>
<p>董事總經理</p>
<p>LifeSci Advisors LLC</p>
<p>Astarr@lifesciadvisors.com</p>
<p>電話：+1 (201) 786-8795</p>
<p>來源：Kazia Therapeutics Limited</p>

KZIA

<p>Kazia Therapeutics 宣佈與機構投資者進行 5000 萬美元的私募股權融資，由專注於醫療保健的公司主導。融資所得將支持其主要項目 paxalisib 的臨牀開發，並將現金流延續至 2028 年。該交易預計將於 2025 年 12 月 3 日完成，具體需滿足相關條件。這些證券未在證券法下注冊，轉售時需要進行貨架註冊聲明</p>

<p>, /PRNewswire/ -- <strong>Kazia Therapeutics Limited (NASDAQ: KZIA)</strong>, an oncology-focused drug development company, today announced that it has entered into a securities purchase agreement with certain established institutional and accredited investors for a private placement of equity securities (PIPE). Pursuant to the securities purchase agreement, the Company agreed to offer and sell to the investors an aggregate of approximately $50.0 million of ordinary shares and prefunded warrants, at a purchase price per share that is the equivalent of $5.00 per ADS, each ADS representing 500 ordinary shares. The PIPE is structured as a straightforward equity investment with no common warrant coverage. The PIPE financing was led by healthcare-dedicated investors including Adar1 Capital Management LLC, Ikarian Capital LLC, Stonepine Capital Management, Velan Capital Investment Management LP, and Revach Capital Management, LLC, alongside existing shareholders, including Jorey Chernett. The transaction is expected to close on Wednesday, December 3, 2025, subject to customary closing conditions.</p>
<div class="lb-trans"><p>/PRNewswire/ -- <strong>Kazia Therapeutics Limited (NASDAQ: KZIA)</strong> 是一家專注於腫瘤學的藥物開發公司，今天宣佈已與一些知名的機構和合格投資者簽署了一項證券購買協議，以進行私募股權融資（PIPE）。根據證券購買協議，公司同意向投資者提供和出售總計約 5000 萬美元的普通股和預先融資的認股權證，每股的購買價格相當於每個美國存托股票（ADS）5.00 美元，每個 ADS 代表 500 股普通股。該 PIPE 融資結構為簡單的股權投資，沒有普通認股權證的覆蓋。PIPE 融資由專注於醫療保健的投資者主導，包括 Adar1 Capital Management LLC、Ikarian Capital LLC、Stonepine Capital Management、Velan Capital Investment Management LP 和 Revach Capital Management, LLC，以及現有股東 Jorey Chernett。該交易預計將在 2025 年 12 月 3 日星期三完成，具體取決於慣例的交割條件。</p>
</div><p>Konik Capital Partners, LLC is acting as the exclusive placement agent for the PIPE.</p>
<div class="lb-trans"><p>Konik Capital Partners, LLC 作為該 PIPE 的獨家配售代理。</p>
</div><p>The net proceeds to the Company from the PIPE are expected to be approximately $46.5million, after deducting placement agent's fees and other estimated offering expenses payable by the Company. The Company currently intends to use the net proceeds from the offering, together with its existing cash, cash equivalents and marketable securities, to support the continued clinical development of its lead program paxalisib, a brain-penetrant dual PI3K/mTOR inhibitor currently in clinical trials for both brain cancer and advanced breast cancer, advancing the PD-L1 degrader program, and for general corporate purposes. The Company expects the net proceeds from the PIPE, combined with the existing cash and cash equivalents, will extend its cash runway into the second half of 2028.</p>
<div class="lb-trans"><p>預計公司從 PIPE 中獲得的淨收益約為 4650 萬美元，扣除配售代理費用和公司需支付的其他估計發行費用。公司目前打算將此次發行的淨收益與現有現金、現金等價物和可交易證券結合使用，以支持其主要項目 paxalisib 的持續臨牀開發，該藥物是一種能夠穿透大腦的雙重 PI3K/mTOR 抑制劑，目前正在進行針對腦癌和晚期乳腺癌的臨牀試驗，推進 PD-L1 降解劑項目，以及用於一般企業用途。公司預計，PIPE 的淨收益與現有現金和現金等價物結合，將使其現金儲備延續到 2028 年下半年。</p>
</div><p>The securities sold in this PIPE are being made in a transaction not involving a public offeringand have not been registered under the Securities Act of 1933, as amended, or applicable state securities laws, and may not be offered or sold inthe United Statesabsent an effective registration statement or an applicable exemption from registration requirements. Pursuant to the securities purchase agreement, the Company has agreed to file a shelf registration statement with the U.S. Securities and Exchange Commission (SEC) within 30 days of the closing to register the resale of ADSs representing the ordinary shares and those underlying the pre-funded warrants.</p>
<div class="lb-trans"><p>在此次 PIPE 中出售的證券是在不涉及公開發行的交易中進行的，未根據《1933 年證券法》及其修訂版或適用的州證券法進行註冊，且在沒有有效註冊聲明或適用的註冊豁免的情況下，可能無法在美國提供或出售。根據證券購買協議，公司已同意在交割後 30 天內向美國證券交易委員會（SEC）提交一份貨架註冊聲明，以註冊代表普通股的 ADS 及其下方的預融資認股權證的轉售。</p>
</div><p>This press release shall not constitute an offer to sell or the solicitation of an offer to buy the securities described herein, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. Any offering of the securities described above under the resale registration statement will only be by means of a prospectus.</p>
<div class="lb-trans"><p>本新聞稿不構成出售證券的要約或購買證券的邀請，也不應在任何州或司法管轄區進行這些證券的銷售，除非在該州或司法管轄區的證券法下注冊或合格之前。根據轉售註冊聲明的任何證券發行將僅通過招股説明書進行。</p>
</div><p><strong>About Kazia Therapeutics Limited</strong></p>
<div class="lb-trans"><p><strong>關於 Kazia Therapeutics Limited</strong></p>
</div><p>Kazia Therapeutics Limited (NASDAQ: <strong>KZIA</strong>) is an innovative oncology-focused drug development company, based inSydney, Australia. Our lead program is paxalisib, a brain-penetrant pan-PI3K/mTOR inhibitor, which is being developed to treat multiple forms of brain cancer, including glioblastoma and brain metastases. A Phase1bclinical trial is also underway evaluating paxalisib in combination with checkpoint inhibition and chemotherapy for patients with advanced triple-negative breast cancer. EVT801, a selective VEGFR3 inhibitor, is currently in a Phase 1 clinical trial for advanced solid tumors. Kazia is working to rapidly progress these assets through clinical development and toward commercialization.</p>
<div class="lb-trans"><p>Kazia Therapeutics Limited (NASDAQ: <strong>KZIA</strong>) 是一家創新的腫瘤學藥物開發公司，總部位於澳大利亞悉尼。我們的主要項目是 paxalisib，一種能夠穿透大腦的全 PI3K/mTOR 抑制劑，正在開發用於治療多種形式的腦癌，包括膠質母細胞瘤和腦轉移。Phase 1b 臨牀試驗也在進行中，評估 paxalisib 與檢查點抑制劑和化療聯合使用，針對晚期三陰性乳腺癌患者。EVT801，一種選擇性 VEGFR3 抑制劑，目前正在進行針對晚期實體瘤的 Phase 1 臨牀試驗。Kazia 正在努力快速推進這些資產的臨牀開發並走向商業化。</p>
</div><p><strong>Forward Looking Statements</strong></p>
<div class="lb-trans"><p><strong>前瞻性聲明</strong></p>
</div><p>This announcement may contain forward-looking statements, within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, which can generally be identified as such by the use of words such as &#34;may,&#34; &#34;will,&#34; &#34;estimate,&#34; &#34;future,&#34; &#34;forward,&#34; &#34;anticipate,&#34; or other similar words. Any statement describing Kazia's future plans, strategies, intentions, expectations, objectives, goals or prospects, and other statements that are not historical facts, are also forward-looking statements, including, but not limited to, statements regarding: the completion of the PIPE, the satisfaction of customary closing conditions related thereto, the intended use of proceeds from the PIPE, the anticipated extension of the Company's cash runway into the second half of 2028 following completion of the PIPE, and the Company's future expectations, plans and prospects. Such statements are based on Kazia's current expectations and projections about future events and future trends affecting its business and are subject to certain risks and uncertainties that could cause actual results to differ materially from those anticipated in the forward-looking statements, including risks and uncertainties: related to market and other conditions, associated with clinical and preclinical trials and product development, including the risk that preliminary or interim data may not reflect final results, related to regulatory approvals, and related to the impact of global economic conditions. These and other risks and uncertainties are described more fully in Kazia's most recent Annual Report, filed on form 20-F with the SEC, and in subsequent filings with the SEC. Kazia undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise, except as required under applicable law. Investors should not place undue reliance on these forward-looking statements, which apply only as of the date of this announcement.</p>
<div class="lb-trans"><p>本公告可能包含前瞻性聲明，符合 1995 年《私人證券訴訟改革法》的定義，這些聲明通常可以通過使用 “可能”、“將”、“估計”、“未來”、“前瞻”、“預期” 或其他類似詞語來識別。任何描述 Kazia 未來計劃、戰略、意圖、期望、目標、目標或前景的聲明，以及其他非歷史事實的聲明，也都是前瞻性聲明，包括但不限於關於：PIPE 的完成、相關的慣例交割條件的滿足、PIPE 收益的預期用途、PIPE 完成後公司現金儲備延續到 2028 年下半年的預期，以及公司的未來期望、計劃和前景。這些聲明基於 Kazia 對未來事件和影響其業務的未來趨勢的當前期望和預測，並受到某些風險和不確定性的影響，這些風險和不確定性可能導致實際結果與前瞻性聲明中預期的結果有重大差異，包括與市場和其他條件相關的風險、與臨牀和前臨牀試驗及產品開發相關的風險，包括初步或中期數據可能不反映最終結果的風險、與監管批准相關的風險，以及與全球經濟狀況的影響相關的風險。這些及其他風險和不確定性在 Kazia 最近提交給 SEC 的 20-F 表格年度報告中有更詳細的描述，以及在隨後的 SEC 文件中。Kazia 沒有義務公開更新任何前瞻性聲明，無論是由於新信息、未來事件還是其他原因，除非法律要求。投資者不應對這些前瞻性聲明過於依賴，這些聲明僅適用於本公告的日期。</p>
</div><p><strong>For further information contact:</strong></p>
<div class="lb-trans"><p><strong>如需進一步信息，請聯繫：</strong></p>
</div><p>Alex Star</p>
<div class="lb-trans"><p>Alex Star</p>
</div><p>Managing Director</p>
<div class="lb-trans"><p>董事總經理</p>
</div><p>LifeSci Advisors LLC</p>
<div class="lb-trans"><p>LifeSci Advisors LLC</p>
</div><p>Astarr@lifesciadvisors.com</p>
<div class="lb-trans"><p>Astarr@lifesciadvisors.com</p>
</div><p>Ph: +1 (201) 786-8795</p>
<div class="lb-trans"><p>電話：+1 (201) 786-8795</p>
</div><p>SOURCE Kazia Therapeutics Limited</p>
<div class="lb-trans"><p>來源：Kazia Therapeutics Limited</p>
</div>

Kazia Therapeutics 宣佈 5000 萬美元股權證券私募的定價 | KZIA 股票新聞